abvcpharma.com - רווח החברה לפני מסים, ריבית ופחת ABVC

ABVC BioPharma develops plant-based medicines dependent on test results and lacks pricing power due to its search for licensing partners. Cash EBITDA visualizes current profit trends, where the parameter has stabilized at 0.00. This micro-developer has no approved drugs and therefore relies entirely on investor capital with zero operating revenue.

To minimize risks when selecting an asset, it is necessary to evaluate the business's ability to generate cash flow before depreciation and interest. This metric captures the actual balance of supply and demand, while the absolute profit from the core operations of ABVC BioPharma reflects the impact of high laboratory costs and a lack of mass sales, which keep the operating leverage at a negative level.